- Aktuelle Seite:
-
Home
-
Substitutionsmittel
- Buprenorphin
Risky Sexual Behavior among Individuals receiving Buprenorphine/Naloxone Opiate Dependency Treatment: HIV Prevention Trials Network (HPTN) 058.
Shava E, Lipira LE, Beauchamp GG, Donnell DJ, Lockman S, Ruan Y, Shao Y.
J Acquir Immune Defic Syndr. 2018 Mar 19. doi: 10.1097/QAI.0000000000001683.
Abstract/accepted article
Does Cannabis Use Influence Opioid Outcomes and Quality of Life Among Buprenorphine Maintained Patients? A Cross-sectional, Comparative Study.
Bagra I, Krishnan V, Rao R, Agrawal A.
J Addict Med. 2018 Mar 14. doi: 10.1097/ADM.0000000000000406.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/29543612
The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine.
Lim SCB, Schug S, Krishnarajah J.
Pain Med. 2018 Jan 3. doi: 10.1093/pm/pnx321.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/29309700
Atomoxetine for amphetamine-type stimulant dependence during buprenorphine treatment: A randomized controlled trial.
Schottenfeld RS, Chawarski MC, Sofuoglu M, Chooi WT, Zaharim NM, M Yasin MA, Ahmad I, Syed Jaapar SZ, Vicknasingam BK.
Drug Alcohol Depend. 2018 Mar 10;186:130-137. doi: 10.1016/j.drugalcdep.2018.01.017.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/29573648
Buprenorphine Formulations: Clinical Best Practice Strategies Recommendations for Perioperative Management of Patients Undergoing Surgical or Interventional Pain Procedures.
Jonan AB, Kaye AD, Urman RD.
Pain Physician. 2018 Jan;21(1):E1-E12.
http://www.painphysicianjournal.com/current/pdf?article=NTAwMQ%3D%3D&journal=109
Perceptions and practices addressing diversion among US buprenorphine prescribers.
Lin LA, Lofwall MR, Walsh SL, Gordon AJ, Knudsen HK.
Drug Alcohol Depend. 2018 Mar 10;186:147-153. doi: 10.1016/j.drugalcdep.2018.01.015.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/29573649
Breathing Problems Linked to Drug that Treats Opioid Addiction
A drug used to treat opioid addiction could cause breathing problems in some obese patients, according to a new study from UT scientists.
Buprenorphine is a Schedule III drug with a lower abuse potential than methadone. It is one of three drugs approved by the US Food and Drug Administration to help patients undergoing treatment for opioid abuse. The UT study found that the drug impairs the ability of obese mice to vary their breathing. These findings in mice may encourage similar studies in humans, since the ability to vary breathing helps us achieve tasks such as climbing stairs and respond to challenges such as disease and surgical stress. (University of Tennessee, 01.02.2018)
https://news.utk.edu/2018/02/01/breathing-problems-linked-to-drug-that-treats-opioid-addiction/
Addressing discordant quantitative urine buprenorphine and norbuprenorphine levels: Case examples in opioid use disorder.
Holt SR, Donroe JH, Cavallo DA, Tetrault JM.
Drug Alcohol Depend. 2018 Mar 2;186:171-174. doi: 10.1016/j.drugalcdep.2017.12.040.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/29579725
Buprenorphine Depresses Respiratory Variability in Obese Mice with Altered Leptin Signaling
Chelsea Angel; Zachary T. Glovak; Wateen Alami; Sara Mihalko; Josh Price; Yandong Jiang; Helen A. Baghdoyan; Ralph Lydic
Anesthesiology. Publish Ahead of Print():, FEB 2018, DOI: 10.1097/ALN.0000000000002073
Issn Print: 0003-3022, Publication Date: 2018/02/02
Abstract
https://insights.ovid.com/crossref?an=00000542-900000000-96963
Effectiveness of Tapering from Methadone or Buprenorphine Maintenance Treatment Compared to Traditional Maintenance Treatment for People with Opiate Addiction: Systematic Review [Internet].
Dalsbø TK, Steiro A, Strømme H, Reinar LM.
Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2017 Mar 2.
https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0098803/
Sexual Dysfunction in Heroin Dependents: A Comparison between Methadone and Buprenorphine Maintenance Treatment.
Yee A, Danaee M, Loh HS, Sulaiman AH, Ng CG (2016)
PLoS ONE 11(1): e0147852. doi.org/10.1371/journal.pone.0147852
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0147852
Buprenorphine Maintenance Subjects Are Hyperalgesic and Have No Antinociceptive Response to a Very High Morphine Dose.
Athanasos P, Ling W, Bochner F, White JM, Somogyi AA.
Pain Med. 2018 Mar 5. doi: 10.1093/pm/pny025.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/29514333
Medications to Treat Opioid Addiction.
NIDA. (2018, January 17).
Transferring Patients From Methadone to Buprenorphine: The Feasibility and Evaluation of Practice Guidelines.
Lintzeris N, Monds LA, Rivas C, Leung S, Dunlop A, Newcombe D, Walters C, Galea S, White N, Montebello M, Demirkol A, Swanson N, Ali R.
J Addict Med. 2018 Mar 5. doi: 10.1097/ADM.0000000000000396.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/29509558
Patterns of non-compliant buprenorphine, levomethadone, and methadone use among opioid dependent persons in treatment.
Casati A, Piontek D, Pfeiffer-Gerschel T.
Subst Abuse Treat Prev Policy. 2014 May 21;9:19. doi: 10.1186/1747-597X-9-19.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4035758/
Umstellung von Methadon / Polamidon auf Buprenorphin – die Ravensburger Strategie
Dr.med. Frank Matschinski; SchwerPunktPraxis Ravensburg, 2013
Treatment of opioid dependence with buprenorphine: current update.
Soyka M.
Dialogues Clin Neurosci. 2017 Sep;19(3):299-308.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741113/
Buprenorphin-Depot: FDA issues complete response letter for CAM2038 for opioid use disorder
Lund, Sweden — 21 January 2018 — Camurus (NASDAQ STO: CAMX) today announced that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the new drug application (NDA) for CAM2038, investigational buprenorphine weekly and monthly depot injections, for the treatment of adults with opioid use disorder (OUD). The FDA has requested additional information to complete the review. There is no need for new clinical studies and the Agency’s requests will be addressed in a timely manner.
“The FDA has issued a complete response letter that will serve as road map for approval and we are confident that the questions raised by the Agency can be effectively managed and resolved”, said Fredrik Tiberg, President & CEO of Camurus. ”Our US partner Braeburn Pharmaceuticals will work closely with the FDA with the goal of bringing CAM2038 to market as quickly as possible.”
CAM2038 has received Fast Track status for treatment of OUD. The NDA was granted FDA Priority Review on 18 September 2017 and FDA Advisory Committee recommended approval on 1 November 2017. If approved, CAM2038 would be the first and only long-acting injectable for individualized treatment of OUD that can be used from start of treatment Day 1 and throughout patients' recovery. (Camurus, Lund/Schweden, 21.01.2018)
http://mb.cision.com/Main/13456/2435148/780076.pdf
Understanding abuse of buprenorphine/naloxone film versus tablet products using data from ASI-MV® substance use disorder treatment centers and RADARS® System Poison Centers.
Butler SF, Black RA, Severtson SG, Dart RC, Green JL.
J Subst Abuse Treat. 2018 Jan;84:42-49. doi: 10.1016/j.jsat.2017.10.010.
http://www.journalofsubstanceabusetreatment.com/article/S0740-5472(17)30354-9/fulltext
Buprenorphine alone or with naloxone: Which is safer?
Kelty E, Cumming C, Troeung L, Hulse G.
J Psychopharmacol. 2018 Feb 1:269881118756015. doi: 10.1177/0269881118756015.
Abstract
Trends in the Use of Methadone, Buprenorphine, and Extended-Release Naltrexone at Substance Abuse Treatment Facilities: 2003-2015 (Update).
Alderks CE.
The CBHSQ Report. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2013-.
https://www.ncbi.nlm.nih.gov/books/NBK469748/
Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine.
Daitch J, Frey ME, Silver D, Mitnick C, Daitch D, Pergolizzi J Jr.
Pain Physician. 2012 Jul;15(3 Suppl):ES59-66.
http://www.painphysicianjournal.com/current/pdf?article=MTcwNg%3D%3D&journal=68